We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Invesco Markets plc NASDAQ Biotech UCITS ETF (SBIO)

Sell:$43.69 Buy:$43.78 0 Change: $0.35 (0.78%)
Market closed Prices as at close on 12 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.35 (0.78%)
Market closed Prices as at close on 12 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.35 (0.78%)
Market closed Prices as at close on 12 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Trade high:
Year high:
Market Listing:
Previous close:
Trade low:
Year low:
$0.16 (0.36%)
Dividend yield:
Data delayed by at least 15 minutes.

ETP Basics

Issuer: Invesco Markets plc
Structure: ETF
Replication method: Swaps
Securities lending: No
Number of holdings: 221
Size: $656.1M
Launch date: 07 November 2014
Launch price: $30.84
Reporting status: Yes
Domicile: Ireland
Complex product: Non-complex
ISIN: IE00BQ70R696

Annual & interim reports

Before you invest, please make sure you read the documents below

Ready to invest?

Invest now

Want to invest?

To buy shares in , you'll need to have an account.

Explore the options

Important Documents

There are no documents available for this stock.


Index: The NASDAQ Biotechnology Index Total Return provides exposure to biotechnology and pharmaceuticals companies (as defined by Industry Classification Benchmark) listed on the NASDAQ Stock Market. Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: • The largest five constituents are capped at 8% • Remaining constituents are capped at 4% • The index is rebalanced quarterly and reviewed annually
Aim: The Invesco NASDAQ Biotech UCITS ETF aims to provide the performance of the NASDAQ...
Read full aim for Invesco Markets plc
Leverage: 100%
Currency hedging: n/a


Ongoing Charge (OCF/TER): 0.40%
Management fee: 0.40%
Indicative spread: 0.21%

In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.


1 week 1W 1.19% 1 year 1Y 1.62%
1 month 1M 4.5% 2 years 2Y 0.85%
3 months 3M 5.6% 3 years 3Y 7.38%
6 months 6M 7.13% 5 years 5Y 22.27%

Performance figures are based on the previous close price. Past performance is not an indication of future performance.

Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Data provided by Broadridge. Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties. Securities lending data correct as at date not available. Charge data correct as at date not available. Holdings correct as at 29 February 2024.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.